November 24, 2023
You are here:  Home  >  Columns  >  Current Article

Silence is deafening when new drugs are not approved


Philip Joens When word leaked that the Food and Drug Administration declined to approve a Novartis biosimilar of an Amgen drug July 19, there was silence from the pharmaceuticals. But when regulators like the FDA or the European Medicines Agency approve new drugs, the news is celebrated by companies as if fireworks should explode and…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.